The pan AKT inhibitor AZD5363 showed a similar pattern of target modulation with about 60% reduction in p-PRAS40 at 4 h and return to baseline within 24 h post-dosing and only limited evidence of antitumor activity in a breast cancer expansion cohort as well [23]. The gene discussed is AKT1; the disease is breast cancer.